title: Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets.
abstract: The aim of the present study was to analyse the effects of combined treatment with calcitriol and phosphate, to find out the incidence of the nephrocalcinosis, and to elucidate the risk factor of nephrocalcinosis in patients with hypophosphatemic rickets. We followed six patients. The median age at diagnosis was 3.25 (0.75-10.5) years. The median follow-up duration was 8.25 (3.5-12.5) years. The mean dose of calcitriol and phosphate treatments was 39.1±8 ng/kg/day, 90.5±57.1 mg/kg/day, respectively. Nephrocalcinosis was detected in three patients (50%). The mean dose of phosphate taken by the patients found to have nephrocalcinosis was detected to be high with a statistically significant difference (p=0.041). No significant relationship was found the mean dose of calcitriol. We found no relationship between the development of nephrocalcinosis and the incidence of hypercalciuria or hypercalcemia episodes. We found the increased phosphate dose administered for treatment to play a role in nephrocalcinosis development.
authors.forename: Melikşah
authors.initials: M
authors.lastname: Keskin
authors.forename: Şenay
authors.initials: Ş
authors.lastname: Savaş-Erdeve
authors.forename: Elif
authors.initials: E
authors.lastname: Sağsak
authors.forename: Semra
authors.initials: S
authors.lastname: Çetinkaya
authors.forename: Zehra
authors.initials: Z
authors.lastname: Aycan
mesh_terms: D000293:Adolescent; D002117:Calcitriol / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D009397:Nephrocalcinosis / Q000453:epidemiology / Q000209:etiology*; D010710:Phosphates / Q000627:therapeutic use; D063730:Rickets, Hypophosphatemic / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D055815:Young Adult
chemical_list: D010710:Phosphates; D002117:Calcitriol